Sunovion seeks FDA nod for sublingual film to treat Parkinson’s disease

Sunovion Pharmaceuticals submitted a new drug application to the FDA this week for its apomorphine sublingual film designed to treat motor fluctuations experienced by people with Parkinson’s disease.

The Marlborough, Mass.-based company is testing the film as a therapy for Parkinson’s patients experiencing “off” episodes – when symptoms that are otherwise controlled by medications resurface. As many as 60% of Parkinson’s patients have these kinds of episodes, according to the company.

“Off episodes, which may be characterized by symptoms such as tremor, stiffness or slow movement, may disrupt the ability to perform everyday activities and may be burdensome for patients, families and caregivers,” Dr. Antony Loebel, EVP & CMO, said in prepared remarks.

Sunovion reported that the therapy performed well compared to a placebo in a pivotal Phase III trial and that the drug’s effect lasted for 90 minutes following initial administration. The film, which has fast-track status with the FDA, was also generally well tolerated by patients in the trial, according to the company.

Sunovion’s drug is gearing up to compete with Acorda Therapeutics‘ (NSDQ:ACOR) inhaled Parkinson’s therapy, Inbrija, which is also under review by the U.S. regulatory agency.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Theranos whistleblower Tyler Shultz to participate in keynote interview at DeviceTalks Boston At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos. Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston. REGISTER NOW